Abstract 349P
Background
Indolent lymphomas, a heterogeneous group of non-Hodgkin lymphomas, exhibit a slow-growing nature and pose distinct clinical challenges due to their potential for relapse and transformation. While standard therapies have demonstrated efficacy in controlling disease progression, efforts to enhance treatment outcomes have led to investigations into combination regimens. Lenalidomide, an immunomodulatory agent with antiangiogenic and antitumor properties, has shown promise in various hematological malignancies. This meta-analysis aim to assess the impact of adding lenalidomide to standard therapy on overall survival (OS) and progression-free survival (PFS) in patients with indolent lymphoma.
Methods
A comprehensive search strategy was employed to identify relevant studies from electronic databases (PubMed, Embase, Web of Science) up to August 2023. Inclusion criteria encompassed randomized controlled trials (RCTs) that compared lenalidomide + standard therapy versus standard therapy alone in patients with indolent lymphoma. Pooled hazard ratios (HRs) for OS and PFS were calculated using random-effects models. Heterogeneity of the pooled analysis was measured by the chi-squared test and I2 statistic. All statistical analyses were conducted using RevMan software (version 5.4; Cochrane Collaboration, London, UK).
Results
The initial search yielded 573 articles, of which 4 randomized controlled trials (RCTs) met the eligibility criteria for inclusion in the meta-analysis. The combined data indicated that there was no statistically significant difference in OS (HR: 0.90; 95% CI: 0.59-1.38; p = 0.63; I2 = 24%) and PFS (HR: 0.76; 95% CI: 0.50-1.50; p = 0.20; I2 = 88%) between patients treated with lenalidomide + standard therapy and those receiving standard therapy alone for indolent lymphoma. Moreover, the use of lenalidomide was not significantly associated with neutropenia (OR: 2.76; 95% CI: 0.72-10.50; p = 0.14; I2 = 95%).
Conclusions
Incorporation of lenalidomide into standard therapy does not yield benefits in both OS and PFS. Due to heterogeneity in PFS and neutropenia pooled analysis, further trials are needed to confirm the results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract